Integrin beta4 promotes DNA damage drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/Rac1
Fang, H.; Ren, W.; Cui, Q.; Liang, H.; Yang, C.; Liu, W.; Wang, X.; Liu, X.; Shi, Y.; Feng, J.; Chen, C.
Show abstract
Anti-tumor drug resistance is a challenge for human triple-negative breast cancer treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote triple-negative breast cancer cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin {beta}4. Integrin {beta}4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in triple-negative breast cancer. These results indicate that the Integrin {beta}4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in triple-negative breast cancer.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells 95%
- METTL3 promotes homologous recombination repair and modulates chemotherapeutic response by regulating the EGF/Rad51 axis 95%
Similar papers in this journal
- Targeting PRMT3 Impairs Methylation and Oligomerization of HSP60 to Boost Anti-Tumor Immunity by Activating cGAS/STING Signaling 95%
- CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer 95%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 94%
Similar papers in this journal
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex 96%
- m6A Demethylase FTO Stabilizes LINK-A to Exert Oncogenic Roles via MCM3-Mediated Cell Cycle Progression and HIF-1α Activation 96%
- A Cancer-Specific Antigen Drives Histone Acetylation by Stabilizing the Acetyltransferases 95%
Similar papers in this journal
- PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer 95%
- EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism 94%
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.